ramatroban
Sign in to saveAlso known as BAY U3405, BAY-U-3405, baynas, EN-137774
Ramatroban (INN; also known as BAY u3405) is a thromboxane receptor antagonist. It is also a DP2 receptor antagonist.
Research
161 papers- Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.Expert opinion on therapeutic targets · 2022
- Ramatroban-Based Analogues Containing Fluorine Group as Potential (18)F-Labeled Positron Emission Tomography (PET) G-Protein Coupled Receptor 44 (GPR44) Tracers.Molecules (Basel, Switzerland) · 2021
- Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor.Cardiovascular drug reviews · 2004
- Ramatroban as a Novel Immunotherapy for COVID-19.Journal of molecular and genetic medicine : an international journal of biomedical research · 2020
- [Ramatroban (Baynas): a review of its pharmacological and clinical profile].Nihon yakurigaku zasshi. Folia pharmacologica Japonica · 2001
via PubMed
~3 min read
Encyclopedic overview
4 sectionsContents
- Synthesis
- See also
- References
- External links
{{Infobox drug | IUPAC_name = 3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid | image = Ramatroban.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = | tradename = Baynas | Drugs.com = | MedlinePlus = | pregnancy_category = | routes_of_administration = Oral (tablets) | legal_status = Rx-only (JP)
Excerpted from Wikipedia’s “ramatroban” article, available under the CC BY-SA 4.0 licence.